D. Boral Capital Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $46.00 price target on the biotechnology company's stock. D. Boral Capital's target price suggests a potential upside of 364.18% from the stock's current price.

Separately, HC Wainwright reiterated a "buy" rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, January 21st.

Anavex Life Sciences Trading Up 0.9 %

NASDAQ:AVXL traded up $0.09 on Tuesday, reaching $9.91. 609,793 shares of the stock traded hands, compared to its average volume of 1,973,641. The company's fifty day simple moving average is $9.92 and its 200 day simple moving average is $7.46. The company has a market capitalization of $840.57 million, a price-to-earnings ratio of -19.06 and a beta of 0.70. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. Equities analysts anticipate that Anavex Life Sciences will post -0.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Anavex Life Sciences

A number of large investors have recently made changes to their positions in the company. Nwam LLC bought a new position in Anavex Life Sciences in the third quarter worth approximately $5,172,000. Renaissance Technologies LLC raised its holdings in Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company's stock worth $1,968,000 after purchasing an additional 386,537 shares during the period. Barclays PLC grew its holdings in Anavex Life Sciences by 70.4% during the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after purchasing an additional 64,101 shares during the period. Geode Capital Management LLC increased its position in Anavex Life Sciences by 2.8% in the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company's stock worth $10,699,000 after buying an additional 51,946 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Anavex Life Sciences in the second quarter worth about $191,000. 31.55% of the stock is currently owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.